Camille Pecnard
Partner
Lavoix
Aude Veinante
European Patent Attorney
Lavoix
Aude assists her clients in defining their patent strategy. Aude drafts new patent applications and monitors grant procedures in France and abroad. Her work also includes conducting patentability, validity and freedom to operate studies as well as forming consultations relative to supplementary protection certificates (SPCs).
Aude performs audits in the pharmaceutical and life science fields and advises her clients in case of patent disputes.
Aude is a member of the AIPPI (International Association for the Protection of Intellectual Property) and the GRAPI (Groupe Rhône-Alpes pour la protection de la Propriété Intellectuelle [Rhône-Alpes Group for the Protection of Intellectual Property]). She is also a lecturer at the Bordeaux National School of Biomolecule Technology.
Pierre-Emmanuel Meynard
Partner
Lavoix
Understanding the Doctrine of Equivalents in the Netherlands.
Mutembei Kariuki
CEO & Co-founder
Fastagger
Mutembei Kariuki is CEO and co-founder of Fastagger, building a pioneering Embodied AI runtime that powers autonomous intelligence on edge devices, from smartphones in the field to robots in extreme environments. He has led global innovation and technology initiatives in edge AI, robotics, and frontier technologies, driving real-time decision-making and scalable AI deployments. Mutembei holds degrees in Economics and Information Systems and trained at the MIT Bootcamp for Launching AI Startups (Tokyo, 2019).
This session provides an in-depth analysis of recent high-profile biologics and biosimilar patent disputes across Europe, the USA, and Asia, including landmark cases involving Xtandi, Soliris, and antibody exclusivity challenges. Attendees will explore how evolving case law, patent claim constructions, and regulatory developments are shaping exclusivity periods, enforcement strategies, and market entry pathways. The session will also address comparative litigation trends, strategic patent considerations, and the complexities of navigating both branded vs branded and biosimilar patent conflicts globally.
• Examine key European rulings on Xtandi and Soliris patents, including patent validity challenges and injunction decisions.
• Analyse evolving antibody patent standards post-G2/21, Amgen vs Sanofi, and their impact on inventive step and exclusivity in the US and Europe.
• Explore strategic insights on BPCIA litigation timing, branded vs branded biologics disputes, and regulatory pathways for biosimilar market entry.
James Holtom
Partner
McCarthy Tetrault